BLI Banque de Luxembourg Investments Acquires New Stake in Stryker Co. (NYSE:SYK)

BLI Banque de Luxembourg Investments acquired a new position in shares of Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,933 shares of the medical technology company's stock, valued at approximately $2,150,000.

Other institutional investors have also recently bought and sold shares of the company. Chicago Capital LLC raised its holdings in Stryker by 3.1% during the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares during the period. Zhang Financial LLC lifted its position in Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after acquiring an additional 40,784 shares in the last quarter. Appleton Partners Inc. MA increased its holdings in Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after purchasing an additional 1,400 shares in the last quarter. Metis Global Partners LLC lifted its holdings in shares of Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after purchasing an additional 1,561 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Stryker by 0.5% in the 4th quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after acquiring an additional 976 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Activity

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.90% of the company's stock.

Stryker Trading Up 1.7 %

NYSE SYK traded up $6.32 during trading hours on Wednesday, hitting $383.84. 1,196,082 shares of the company's stock were exchanged, compared to its average volume of 1,357,851. The firm has a market cap of $146.51 billion, a price-to-earnings ratio of 49.46, a PEG ratio of 2.93 and a beta of 0.93. The stock has a 50-day simple moving average of $365.90 and a 200 day simple moving average of $374.10. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period last year, the company posted $2.50 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis. On average, equities analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Analysts Set New Price Targets

SYK has been the subject of a number of research analyst reports. Roth Mkm lifted their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Truist Financial upped their target price on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday. JPMorgan Chase & Co. increased their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a research report on Monday. Finally, Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $427.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.